(3S)-3-[[[(2R,3R,4R,5R)-5-(2-amino-6-ethoxypurin-9-yl)-3-hydroxy-4-methyl-4-methylsulfanyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]butan-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (3S)-3-[[[(2R,3R,4R,5R)-5-(2-amino-6-ethoxypurin-9-yl)-3-hydroxy-4-methyl-4-methylsulfanyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]butan-2-one
• 化学式: C₂₈H₃₅N₆O₇PS
• 分子量: 630.7
• InChiKey: KPJCCEXHECOIGG-FQYYWCBUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  198
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Girijavallabhan Vinay

  公开号：US20140154211A1

  公开（公告）日：2014-06-05

  The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R 1 , R 2 and R 3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Substituted Nucleoside Derivative, and methods of using the 2′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
• US9061041B2
  申请人：——

  公开号：US9061041B2

  公开（公告）日：2015-06-23